New analyses of Phase 3 Dupixent (dupilumab) data in adults, adolescents, and children with atopic dermatitis will be presented at the 2020 European Academy of Dermatology and Venereology (EADV) Virtual Congress from October 29-31.

Presentations include data from open-label extension trials evaluating laboratory assessments in adults treated with Dupixent for up to three years and adolescents (aged 12 to 17 years) treated up to one year. These data reinforce the well-established long-term safety profile of Dupixent in moderate-to-severe atopic dermatitis, which does not require initial blood testing or ongoing laboratory monitoring.

Additionally, data will be presented from trials that assessed the impact of Dupixent, measured as early as 2 weeks after the first dose, on signs and symptoms including itch, oozing/crusting, swelling and sleep disturbance, using SCOring Atopic Dermatitis (SCORAD) in adolescents with moderate-to-severe disease and children (aged 6 to 11 years) with severe disease.

“Our new data at EADV build on the existing wealth of evidence supporting the unique way Dupixent specifically targets the underlying type 2 inflammation that contributes to diseases like atopic dermatitis, thus significantly improving itch and skin lesions and other important measures that impact a patient’s quality of life,” said Paul Rowe, MD, ATSF, Vice President, Head of Global Medical, Immunology at Sanofi Genzyme. “We will also present data from the adult trial showing how the majority of patients reported high satisfaction with Dupixent after long-term treatment up to three years, which is very important when treating a life-long chronic disease like atopic dermatitis.”